The safety and efficacy of a low-dose monophasic oral contraceptive (OC) containing a new
progestogen, gestodene (GTD), combined with ethinyl estradiol (EE) is being investigated in …

A multicenter trial was carried out by 13 independent German investigators to evaluate a
new oral contraceptive combination containing 0.150 mg desogestrel+ 0.020 mg …

The clinical and metabolic effects of the gestodene-containing oral contraceptive (OC) was
tested in 50 normal adolescents who received the monophasic 75 mg gestodene/30 μg …

The newer progestogens gestodene, desogestrel and norgestimate were developed in an
attempt to produce agents with more selective progestational activity that would improve …

In this double-blind study we compared the influence of two oral contraceptives, a 23-day
regimen with 20 μg ethinyl estradiol and 75 μg gestodene (23-day 20/75) and a 21-day …

Single doses of ethynylestradiol (30 μg) were given alone and in combination with either
gestodene (75 μg) or desogestrel (150 μg) to 10 healthy female volunteers. The doses of …

A multicenter trial was conducted in 267 centers in Italy to evaluate the efficacy, acceptability
and safety of a monophasic oral contraceptive containing 30 micrograms ethinyl estradiol …

The efficacy and safety of the low dose monophasic oral contraceptive (OC) combination
containing 30 µg of ethinylestradiol (EE) and 2.0 mg of dienogest (DNG)(EE/DNG) was …

The objective of this prospective study was to assess the effects of a low-dose oral
contraceptive (OC) containing 15 μg ethinylestradiol and 60 μg gestodene on sexuality …

Objectives This study aims to assess vaginal bleeding patterns and cycle control of oral
contraceptives containing estetrol (E4) combined with either drospirenone (DRSP) or …